U.S. markets have recovered following 2022’s historic selloff, leading some to question what comes next. In this environment, we believe certain active approaches are better positioned to benefit than others.
Executive Managing Director and Sr. Portfolio Manager Brian Christiansen discusses the importance of candor and collaboration in a culture that promotes long-term thinking.
Recruit Holdings is transforming the world of work through wage transparency and providing life-changing opportunities for immigrants and refugees.
Our second annual stewardship report reflects our commitment to provide clients and other key stakeholders with transparency into our initiatives, actions, and the progress we made in 2022.
Our life sciences strategy looks to invest in promising life sciences companies that we believe are at the heart of a technological and scientific revolution in healthcare.
Director of Technical Research
Farcast Biosciences (2017-2020)
Bangalore, India | Director R&D, Intellectual Property
General Electric (2010 - 2017)
Bangalore, India | Lead Intellectual Property Professional
Brigham & Women’s Hospital, Harvard-MIT Division of Health Science and Technology (2007 - 2010)
Cambridge, MA | Post-doctoral fellow
Indian Institute of Science (2002-2007)
PhD | Organic Chemistry
Indian Institute of Science (1999 - 2002)
Master of Science | Chemical Sciences
Padmaparna joined Sands Capital in 2022 as the Director of Technical Research, reporting to Parker Cassidy. Prior to that, Padmaparna spent 12 years in large multi-national and startup companies, working across different life sciences tools and diagnostic programs. In those roles, she has led the creation of patent portfolios and performed technology and intellectual property analysis to identify R&D and inorganic growth opportunities. The work contributed to initiation and shaping of various internal research programs, and led to some key collaborations/acquisitions. Padmaparna did her PhD from Indian Institute of Science (India) in Bioorganic Chemistry and her post-doctoral research in Harvard Medical School/Brigham & Women’s Hospital in the area of targeted drug delivery in cancer.